Logo

M2Gen: Helge Bastian

Aug 30, 2019

Health informatics firm M2Gen recently appointed Helge Bastian as president and CEO. Bastian succeeds William Dalton, executive chair of the firm and interim CEO since September 2018. Bastian joins M2Gen from Thermo Fisher Scientific, where he led the sample preparation and synthetic biology businesses as vice president and general manager since 2014. Before that, he held a number of senior leadership positions and served as a member of several executive leadership teams, including managing director and chief commercial officer at Indivumed; vice president of global marketing, business development, and strategy at Sigma-Aldrich (now Merck KGaA); executive vice president of life science services for SGS; and various management positions at Qiagen including vice president of molecular diagnostics, VP of global strategic marketing, and VP of PreAnalytiX, a Qiagen/Becton Dickinson joint venture.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.